A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center study to evaluate the efficacy and safety of SHR-1701 in
combination with famitinib in subjects with metastatic or locally advanced solid tumor. There
are two parts of the study: combinational therapy part and monotherapy part. Phase I of
combinational therapy part is to determine the recommended dose for Phase II (RP2D) for
famitinib in the combined regimen, then efficacy and safety of SHR-1701 plus famitinib (RP2D)
will be further evaluated in the following Phase II in cohorts 1/2/3, with simon's two-stage
design. Meanwhile, efficacy and safety of famitinib will also be assessed in cohorts 4/5 in
the monotherapy part.